Systemic therapy for metastatic colorectal cancer: current questions (Q37109507)

18 August 2017

title

Systemic therapy for metastatic colorectal cancer: current questions (English)

1 reference

18 August 2017

1 reference

metastatic colon cancer

1 reference

1 reference

1 reference

Dan S Zuckerman

1 reference

18 August 2017

Jeffrey W Clark

series ordinal

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

112

1 reference

18 August 2017

1 reference

18 August 2017

page(s)

1879-1891

1 reference

Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

The continuum of care: a paradigm for the management of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Systemic therapy for metastatic colorectal cancer: current options, current evidence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Systemic therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Trends in long-term survival following liver resection for hepatic colorectal metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Hepatic arterial infusion after liver resection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Complete response of colorectal liver metastases after chemotherapy: does it mean cure?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Pharmacogenomics and colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23409

7 January 2021

Identifiers

DOI

10.1002/CNCR.23409

1 reference

18 August 2017

1 reference